Association Between Early Severe Cardiovascular Events and the Initiation of Treatment With the Anti–Interleukin 12/23p40 Antibody Ustekinumab

French case-time-control study (n=9290) suggests initiation of ustekinumab may trigger severe CV events (ACS, unstable angina, stroke) among patients at high CV risk (odds ratio, 4.17; 95% CI, 1.19-14.59) but no significant association among patients with low CV risk.


JAMA Dermatology